The binding of the receptor for advanced glycation end products (RAGE) with its ligands begins a sustained period of cellular activation and inflammatory signal amplification in different tissues and diseases. This binding could represent an as yet uninvestigated pathway of inflammatory reaction in the lung, where the presence of the receptor has been largely documented and advanced glycation end products (AGEs) are produced by nonenzymatic glycation and oxidation of proteins and lipids, driven by smoke and pollutants exposure or inflammatory stress. We immunohistochemically assessed the expression of RAGE and of its major proinflammatory ligands, N-e-carboxy-methyl-lysine, S100B and S-100A12 in normal lung and in nonneoplastic lung disorders including smoke-related airway disease, granulomatous inflammation, postobstructive damage and usual interstitial pneumonia. In normal lung low expression of the receptor was observed in bronchiolar epithelia, type II pneumocytes, macrophages and some endothelia. S100A12 and S100B were expressed, respectively, in granulocytes and in dendritic cells. Carboxy-methyl-lysine was present in bronchiolar epithelia and macrophages. In all pathological conditions associated with inflammation and lung damage overexpression of both the receptor and of AGEs was observed in bronchiolar epithelia, type II alveolar pneumocytes, alveolar macrophages and endothelia. RAGE overexpression was more evident in epithelia associated with inflammatory cell aggregates. Fibroblasts in usual interstitial pneumonia expressed both the receptor and AGEs. The number of S100A12 and S100B immunoreactive inflammatory cells was variable. S100A12 was also expressed in mononuclear inflammatory cells and in activated epithelia. The activation of the inflammatory pathway controlled by the RAGE is not specific of a single lung disease, however, it may be relevant as a nonspecific pathway of sustained inflammation in lung tissue, and on this basis therapeutic approaches based on receptor blockage can be envisaged.
The receptor for advanced glycation end products (RAGE) is a multiligand membrane receptor able to engage classes of unrelated molecules, recognizing their tertiary structures rather than amino-acid sequences. 1, 2 Major ligands of RAGE comprise heterogeneous groups of molecules, such as advanced glycation end products (AGEs), proinflammatory cytokine-like mediators of the S100/ calgranulin family (S100A12 and S100B), amphoterin and b-sheet fibrils of amyloid. While the interaction of RAGE with the last two molecules seems to be involved in rather specific processes, namely neurite outgrowth and tumor cell invasion and migration, 1 and neuronal activation and apoptosis in Alzheimer disease, RAGE binding with AGEs and S100/calgranulins has been involved in a rapidly expanding series of inflammatory conditions associated with diabetes, 3 atherosclerosis 2,4 and rheumatological disorders. 5, 6 Ligand binding to RAGE does not accelerate their clearance or degradation but rather begins a sustained period of cellular activation mediated by receptor-dependent signaling and RAGE overepression. Proinflamma-tory RAGE ligands comprise several families of unrelated molecules: AGEs are a heterogeneous group of compounds deriving from the nonenzymatic glycation and oxidation of proteins and lipids; their formation in several pathophysiologic situations associated with inflammation is triggered by oxidant stress. 7 The S100/calgranulins are a family of closely related calcium-binding polypeptides, which have been implicated in the regulation of protein phosphorylation, Ca 2 þ homeostasis, enzyme and transcription factor activities, cell growth and differentiation and in the inflammatory response. 8 S100A12 and S100-B have been shown to activate endothelia, vascular smooth muscle cells, monocytes and T cells via RAGE, resulting in the generation of cytokines and proinflammatory adhesion molecules. 2, 5 Moreover, S100A12-calgranulin is expressed in polymorphonuclear granulocytes and is present in the serum in a wide range of inflammatory diseases. [9] [10] [11] RAGE is expressed at low levels in normal tissues and in the vessels and becomes upregulated at sites where its ligands accumulate.
1,2 RAGE was initially extracted and sequenced from bovine lung. 12, 13 Subsequent immunohistochemical and hybridization studies confirmed its presence in bovine, rat and human lung. [14] [15] [16] Recently, an extensive immunohistochemical survey of normal human tissues showed RAGE expression in type II alveolar pneumocytes, endothelia and alveolar macrophages. 17 On the basis of these data, we speculated that RAGE-ligand interaction could represent an as yet uninvestigated pathway of inflammatory reaction in the lung. In particular, lungs are sites of intense oxidative activity by reactive oxygen intermediates both in airways, as a consequence of smoke and pollutant exposure, 18, 19 and in peripheral parenchyma, as a result of inflammatory stress. 20, 21 We aimed, with the present study, at investigating the activation of this inflammatory pathway in lung pathology by assessing the pattern of expression of RAGE and of its major proinflammatory ligands, N-e-carboxy-methyl-lysine, S100B and S-100A12 in normal lung and in several common non-neoplastic lung disorders.
Materials and methods

Case Series
Lung samples obtained at video-assisted thoracoscopy performed for the diagnosis of interstitial lung diseases, and samples of non-neoplastic tissue obtained from lobectomies performed in patients with lung cancer were used for the study.
Samples obtained at video-assisted thoracoscopy included 10 usual interstitial pneumonias, five organizing pneumonias, seven sarcoidosis, three Langerhans cell histiocytosis and two tuberculosis. Non-neoplastic samples from lobectomies included six histologically normal samples from nonsmokers, 15 samples with histological evidence of smokeinduced lesions (chronic bronchiolitis, peribronchiolar fibrosis, pigmented macrophages, emphysema) from smokers, seven of whom had also clinical evidence of chronic obstructive pulmonary disease and six samples showing nonspecific inflammation associated with proximal neoplastic airway obstruction. All cases were reviewed to confirm the original diagnosis according to more recent classification criteria. 22 
Immunohistochemistry
Sections of formalin-fixed, paraffin-embedded samples were incubated with a goat antibody specific for amino acids 42-59 of the extracellular domain of RAGE (V-type domain) (Abcam, Cambridge, UK), and with antibodies against RAGE ligands: N-e-(carboxymethyl)-lysine, one of the major components of AGEs (TransGenic Inc., Kumamoto, Japan), S100B (DakoCytomation, Carpinteria, CA, USA), and S-100 A12 (Santa Cruz Biotechnologies, Santa Cruz, CA, USA). Working dilutions were 1:4000 for RAGE and S-100A12 and 1:1000 for carboxy-methyl-lysine and S100B. Microwave oven pretreatment in pH6 citrate buffer was required for s100B immunoreactions. The reactions were revealed using peroxidase-conjugated avidinbiotin complex (LSAB-plus kit, DakoCytomation) and diaminobenzidine tetrahydrocloride as chromogen substrate (DakoCytomation). Each reaction set included a negative control obtained with substitution of the primary antibody with dilution buffer. Immunohistochemical reactions were evaluated by a pathologist, who recorded the presence of immune reactivity and the cell types expressing each antigen. The intensity of expression in any given cell type (or extracellular fluid) was semiquantitatively assessed as low or high as a function of the degree of brown diaminobenzidine stain. Overall, all cells of a given type showed a similar degree of immunoreactivity.
Results
The results detailed in the following paragraphs are summarized in Table 1 .
Normal Lung
In normal lung (Figure 1a , c, e), low to intermediate RAGE immunoreactivity was observed in bronchiolar epithelia, type II alveolar pneumocytes and alveolar macrophages; large-sized vessel endothelia were also faintly stained. S100A12 and S100B were expressed, respectively, in sparse, mainly intravascular, polymorphonuclear granulocytes, and in rare interstitial dendritic cells, mainly in subepithelial location. Peribronchial nerves were also immunoreactive for S100B. Carboxy-methyl-lysine localiza-tion was similar to that of RAGE in bronchiolar epithelia and macrophages; it was only slightly expressed in type II pneumocytes; endothelia were negative. Intravascular serum was occasionally reactive for RAGE, carboxy-methyl-lysine and S100A12.
Smoke-Related Pulmonary Disease
Lungs with lesions related to smoking (Figure 1b, d , f, h) showed extensive RAGE reactivity in bronchiolar epithelia and in areas of alveolar bronchiolization, as well as in reactive pneumocytes. Epithelial cells closely related to inflammatory infiltrates were strongly immunoreactive for RAGE (Figure 2a ). Alveolar macrophages and endothelia were also positive. S100A12 was observed in polymorphonuclear granulocytes and in extracellular fluid. Low reactivity was present in bronchiolar epithelia and in some macrophages. The number of submucosal S100B-reactive dendritic cells was increased in bronchiolar walls, as expected in smokers. High levels of carboxy-methyl-lysine expression were present in alveolar macrophages, in bronchiolar epithelia, in reactive alveolar epithelia, and in extracellular fluids. Endothelia were frequently reactive for carboxy-methyl-lysine. Table 1 Distribution of immunoreactivity and intensity of staining in different cell types in normal lung and common non-neoplastic lung disorders
RAGE
Carboxy-methyl-lysine S100A12 S100B
Normal lung Bronchiolar epithelia (Figure 3) The presence of diffuse alveolar epithelial hyperplasia was associated with marked expression of RAGE in type II pneumocytes, which was highest in epithelia overlying lymphocytic nodular aggregates (Figure 2b) . Endothelia, sparse fibroblasts and macrophages also expressed RAGE. The expression of S100B and S100A12 was increased in accordance with the increased number or polymorphonuclear and dendritic inflammatory cells; bronchiolar but not alveolar epithelia were faintly reactive for S100A12. Carboxy-methyl-lysine localization overlapped that of RAGE, being less intense in epithelial cells (Figure 2c ). Where alveolar exudate was present, it showed reactivity for RAGE, carboxymethyl-lysine and S100A12.
Organizing Pneumonia
RAGE was present in hyperplastic alveolar epithelia, even those covering Masson bodies, and in bronchiolar epithelia; endothelia and macrophages were also highly immunoreactive. Some elongated cells of endoalveolar fibroblastic polyps expressed RAGE. Carboxy-methyl-lysine localization overlapped that of RAGE, with lower reactivity in epithelial cells. S100B and S100A12 were expressed respectively in dendritic and polymorphonuclear inflammatory cells; in half of the cases, hyperplastic type II pneumocytes and some alveolar macrophages also expressed a low degree of S100A12 reactivity.
Where alveolar exudate was present, it showed reactivity for RAGE, carboxy-methyl-lysine and S100A12.
Granulomatous Lung Disorders (Figure 3)
Epithelioid and giant cells from sarcoid and tuberculous granulomas expressed RAGE at high levels; hyperplastic alveolar epithelia close to granulomas were also strongly immunoreactive. Histiocytes and giant cells of granulomas also expressed S100A12 and carboxy-methyl-lysine, and were infiltrated by S100B-reactive dendritic cells. Immunoreactivity of sarcoidosis samples for RAGE, S100A12, S100B and carboxy-methyl-lysine has been extensively investigated in a separate paper (Campo I et al, submitted 23 ). Cellular infiltrates of Langerhans cell histiocytosis were highly reactive for RAGE, S100B and carboxy-methyl-lysine but not for S100A12.
Usual Interstitial Pneumonia (Figure 3)
RAGE and carboxy-methyl-lysine were highly overexpressed in usual interstitial pneumonia, in reactive pneumocytes, bronchiolar metaplastic epithelium, and in endothelia. Carboxy-methyllysine, and, to a lesser extent, RAGE were present in the alveolar fluid. The number of infiltrating cells immunoreactive for S100B and S100A12 was variable from case to case. S100A12 reactivity was also present in reactive/hyperplastic pneumocytes, in part of alveolar macrophages, in some endothelia and in the alveolar fluid. Fibroblastic foci showed RAGE and carboxy-methyl-lysine reactivity both in the epithelial component and in the fibroblastic cells; epithelial cells also expressed S100A12 (Figure 4 ).
Discussion
The role of RAGE and its ligands in maintaining and amplifying inflammation has only recently been highlighted. RAGE-mediated tissue damage is being involved in chronic inflammatory pathology of multiple organs. 5 The results of the present study suggest that the inflammatory pathway associated with RAGE-ligand binding could have a role also in chronic lung diseases. To date, RAGE had been identified in type II pneumocytes and macrophages from normal human lungs, 17 and in type I pneumocytes of rat lung, where it was suggested as a marker of acute lung injury. 24 Carboxy-methyl-lysine, the major component of AGEs, has been observed in bronchial epithelia and macrophages. 25 Our study documented that low levels of RAGE are expressed in normal conditions in bronchial epithelia, type II pneumocytes, endothelia and macrophages, and that RAGE overexpression occurs in all pathological conditions associated with inflammation and lung damage. The increase in RAGE expression was not only due to the increased number of reactive pneumocytes and macrophages, which constitutively expressed RAGE in normal lungs, but also to the higher immunoreactivity observed in these cells with respect to normal conditions. In particular, RAGE was expressed at highest rate in pneumocytes and airway epithelia associated with inflammatory infiltrates. Moreover, we observed consistent RAGE expression in inflammatory cells, in particular in granulomas. 23 As far as ligands are concerned, RAGE and AGE reactivity were similar in distribution and intensity, while the number of S100A12 and S100B immunoreactive inflammatory cells was highly variable. S100B reactivity was restricted to normal and pathologic dendritic cells; S100A12 was not only expressed in polymorphonuclear granulocytes and in cells of monocytic lineage (epithelioid and giant cells of granulomas) but also in activated epithelial cells. RAGE, S100A12 and carboxymethyl-lysine were also present in the serum and in endoalveolar fluid in inflammation.
A recent paper documented the presence of AGEs in macrophages and hyperplastic epithelia of lungs with usual interstitial pneumonia, but not of normal controls. The authors suggested that AGE-mediated activation of macrophages through binding with specific receptors could have a role in the fibrogenic process, since macrophages were stimulated to produce several cytokines and growth factors, such as TNF, IL-1, and PDGF, and mediators of oxidative stress. 26 Our study confirmed this observation, documenting that AGE and RAGE are coexpressed not only in inflammatory cells but also in reactive epithelial cells and fibroblasts in usual interstitial pneumonia and in several inflammatory and fibrosing pulmonary conditions, and that RAGE ligands of the S100-calgranulin family are synchronously present in different inflammatory cell populations. The production of AGE-modified proteins as a consequence of the oxidative stress associated both with pulmonary inflammation and with usual interstitial pneumonia 21, 22, 27, 28 and their binding with RAGE on different cell types can be considered as a possible, as yet not investigated, mechanism of cellular activation that leads to pulmonary tissue damage and fibrosis. In accordance with this hypothesis, NfkB, one downstream product of RAGE-mediated cellular activation, has been shown to have a specific binding site on the promoter of TGF-b1, 29 which is considered one of the key mediators in pulmonary fibrosis. 30 Moreover, most of the cytokines induced by RAGE cellular activation have a profibrotic role in the lung. 31 We also observed that, in normal lung, RAGE and carboxy-methyl-lysine were expressed in ciliated bronchial and bronchiolar epithelia. The number of RAGE and carboxy-methyl-lysine reactive cells and the intensity of expression were markedly increased in the lung of smokers both in epithelial and inflammatory cells. As smoke is associated with oxidative damage in the airway cells, 18, 19 it is possible that oxidative damage in bronchial/olar epithelia drives the production of AGE-modified proteins with subsequent activation of RAGE in epithelial and inflammatory cells, and RAGEmediated sustained inflammation and cytokine production. Interestingly, incubation with nornicotine has recently been shown to induce RAGE upregulation in human gingival fibroblasts, involving RAGE in smoke-related periodontal disease. 32 Further studies are needed to clarify the association of RAGE with smoking and airway damage. RAGE-ligand expression in non-neoplastic lung diseases P Morbini et al sRAGE is a secreted form of the receptor produced by alternative splicing of RAGE mRNA and is present in serum and alveolar exudate. 33 The exogenous administration of this last splice variant has been demonstrated in experimental settings to have a negative role on RAGE-mediated proinflammatory action, since it prevents RAGE ligands from binding with the active, membrane-bound, receptor. 34 Controversial data exist on the relative distribution of different RAGE isoforms in normal tissues: a recent report has shown that sRAGE is the prevalent form expressed intracellularly in normal human tissues, 17 suggesting that it may have other roles than binding AGEs. 17 However, in the lung the occurrence of the full-length membranebound receptor has been documented both with immunohistochemistry and RT-PCR. 17, 33 As the antibody used for RAGE investigation binds with the extracellular V-type domain of the protein, which is present on both the full-length transmembrane receptor and on the C-terminally truncated secretory forms we were unable to discriminate the active form of the transmembrane receptor from the secretory forms stored in the cytoplasm. However, the limited expression of RAGE in normal pulmonary tissue, the concomitant marked increase of RAGE and RAGE ligands expression in a wide range of full-blown inflammatory conditions, and the recent observation of full length and sRAGE, respectively, in alveolar epithelia and alveolar fluid in a rat model of diffuse alveolar damage 24 suggest that most intracellular RAGE is the full-length isoform.
The observed highest expression of RAGE in alveolar and bronchiolar epithelia associated with inflammatory infiltrates is particularly interesting and is in accordance with the previous hypothesis that RAGE and its ligands may contribute to cell to cell binding and activation, similarly to the interaction of costimulatory molecules B7-1/B7-2 with Figure 3 RAGE and RAGE ligand expression in nonspecific parenchymal inflammation and organization distal to neoplastic airway obstruction (postobstructive pneumonia), necrotizing granulomatous disease associated with mycobacterium tuberculosis infection, and in fibrotic lung disease with usual interstitial pneumonia pattern. In nonspecific parenchymal damage (a) RAGE and (d) carboxy-methyllysine are expressed in reactive type II pneumocytes and in inflammatory cells; (g) only scattered polymorphonuclear granulocytes express S100A12. In infective granulomas, epithelioid histiocytes and giant cells are reactive for (b) RAGE, (e) carboxy-methyl-lysine and (h) S100A12 (these cells do not express S100B data no shown). In usual interstitial pneumonia both hyperplastic epithelial and interstitial cells express (c) RAGE, (f) carboxy-methyl-lysine and (i) S100A12 (S100B is not expressed in the same cells, data no shown). CD28. 1 The coexpression of carboxy-methyl-lysine in the same cells suggests that in this setting RAGEmediated cellular activation might have a role in the formation of lymphoid aggregates, which have been associated with smoke-related airway obstruction. 35 All data collected so far in different organ systems and pathological settings point toward a role of RAGE not as a causative or initiating factor for diseases, but rather as a mediator of amplification of chronic cellular activation and dysfunction. 1 Consensus exists that ligand-RAGE interaction sustains the host response eventuating in chronic injury. The present study has contributed to extend the spectrum of RAGE-mediated diseases to lung inflammation and damage. The activation of RAGE inflammatory pathway is by no means specific of a single lung disease, since is has been observed in conditions ranging from smoke-induced bronchial damage to granulomatous disorders, to idiopathic pulmonary fibrosis. However, RAGE activation may be relevant as a nonspecific pathway of sustained inflammation in lung tissue, and on this basis therapeutic approaches based on RAGE blockage can be envisaged. 
